Ascendis Health shareholders took the company's leadership to task this week, demanding answers as to why the ailing company was dragging its feet on finalising the sale of its Remedica business.

At its AGM on Wednesday the company said the deal to sell Remedica for which it signed an exclusivity agreement, had been scuppered by the bidder's noncompliant submission regarding how it would fund the sale. Shareholders were not impressed...

BL Premium

This article is reserved for our subscribers.

A subscription helps you enjoy the best of our business content every day along with benefits such as articles from our international business news partners; ProfileData financial data; and digital access to the Sunday Times and Sunday Times Daily.

Already subscribed? Simply sign in below.

Questions or problems? Email or call 0860 52 52 00. Got a subscription voucher? Redeem it now